AMRI and PerkinElmer Join Hands on Drug Discovery and Development
FREMONT, CA: Looking forward to the growing bio-pharma sector, Albany Molecular Research (AMRI), a contract research and manufacturing organization for Life Sciences industry and PerkinElmer, a company focused on improving the health and safety of people and the environment have signed a collaborative deal in connection with the opening of AMRI’s new drug discovery center which will be co-located on the Buffalo Niagara Medical Campus.
The collaboration will promote drug discovery and innovation with a foundation for new research and development opportunities, thereby accelerating the expansion of the new Buffalo Medical Innovation and Commercialization Hub (BMIC).AMRI will work with BMIC, various customers and partners to provide drug discovery solutions and translational science needs.
PerkinElmer will arrange technical and informatics experts to facilitate technological and drug discovery innovations and also provide informatics technologies and high content screening, cellular imaging, and analytical instruments. AMRI's chemistry and biology expertise together with PerkinElmer’s services will help scientists at the BMIC hub in research and development.
"PerkinElmer's technologies will provide us with the ability to acquire, manage, integrate and analyze large complex data from the various translational platforms needed to drive better decisions in drug discovery. This will enable us to accelerate the knowledge and information our customers and partners need and strengthen our end-to-end integrated discovery offerings”, says Dr. Michael A. Luther, Senior VP, Discovery and Development, AMRI.